经动脉化疗栓塞联合索拉非尼治疗不可切除肝细胞癌的安全性 - Suppr | 超能文献

Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.

作者信息

Sinakos Emmanouil, Dedes Ioannis, Papalavrentios Lavrentis, Drevelegas Antonios, Akriviadis Evangelos

出版信息

Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335.

DOI:10.3109/00365521003628335

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.经动脉化疗栓塞联合索拉非尼治疗不可切除肝细胞癌的安全性

Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335.

2

Major achievements in hepatocellular carcinoma.肝细胞癌的主要成就。

Lancet. 2009 Feb 21;373(9664):614-6. doi: 10.1016/S0140-6736(09)60381-0.

3

TACE with or without systemic therapy?肝动脉化疗栓塞术联合或不联合全身治疗？

J Hepatol. 2012 Jun;56(6):1224-5. doi: 10.1016/j.jhep.2012.02.011. Epub 2012 Mar 5.

4

Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.索拉非尼持续给药联合改良经动脉化疗栓塞术治疗不可切除肝细胞癌患者的临床价值

Chin Med J (Engl). 2013 Jan;126(2):385-6.

5

Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?经动脉化疗栓塞术与索拉非尼治疗中期肝细胞癌患者：是时候进入常规临床实践了吗？

Future Oncol. 2015;11(17):2371-3. doi: 10.2217/FON.15.173. Epub 2015 Aug 13.

6

Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.同期经动脉化疗栓塞和索拉非尼治疗不可切除肝细胞癌的 II 期研究。

J Hepatol. 2012 Jun;56(6):1336-42. doi: 10.1016/j.jhep.2012.01.006. Epub 2012 Feb 4.

7

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].肝移植前肝细胞癌患者经动脉化疗栓塞术（TACE）联合索拉非尼与TACE加安慰剂对比的前瞻性、随机、双盲、多中心III期临床研究——HeiLivCa [国际标准随机对照试验编号：ISRCTN24081794]

BMC Cancer. 2008 Nov 26;8:349. doi: 10.1186/1471-2407-8-349.

8

The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.索拉非尼联合经动脉化疗栓塞治疗肝细胞癌。

Aliment Pharmacol Ther. 2011 Jul;34(2):205-13. doi: 10.1111/j.1365-2036.2011.04697.x. Epub 2011 May 23.

9

Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.索拉非尼联合经动脉化疗栓塞术治疗肝细胞癌。

Clin Adv Hematol Oncol. 2016 Aug;14(8):585-7.

10

Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.索拉非尼联合经动脉化疗栓塞可提高不可切除肝细胞癌患者的生存率：一项倾向评分匹配研究。

J Dig Dis. 2013 Apr;14(4):181-90. doi: 10.1111/1751-2980.12038.

引用本文的文献

1

The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence.索拉非尼在肝移植前缩小肝细胞癌体积及治疗肿瘤复发中的作用。

Ann Gastroenterol. 2011;24(3):228-230.

2

Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.索拉非尼持续给药联合经动脉化疗栓塞治疗肝细胞癌患者：一项 I 期研究结果。

Oncologist. 2010;15(11):1198-204. doi: 10.1634/theoncologist.2010-0180. Epub 2010 Oct 29.